<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00611910</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. S02707</org_study_id>
    <nct_id>NCT00611910</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions</brief_title>
  <acronym>ISAR-CABG</acronym>
  <official_title>Prospective, Randomized Trial of Drug-eluting Stents vs. Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of drug-eluting stents and bare metal stents
      to reduce reblockage of bypass grafts after coronary stenting
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A large number of studies showed that drug-eluting stents significantly reduce in-stent
      restenosis and the subsequent need for target vessel revascularisation compared with bare
      metal stents. Although this applies to the vast majority of patients, intimal hyperplasia and
      in-stent restenosis have not been completely eliminated and remain to occur in certain high
      risk subgroups. While there is a plenty of data about the efficacy of DES in complex lesions
      or diabetics, no randomized data exist about the efficacy of DES in coronary artery bypass
      graft lesions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point of the study is composite of death, myocardial infarction and target lesion revascularization at one year after stent implantation</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of target lesion revascularization (TLR), defined as any revascularization procedure involving the target lesion due to luminal re-narrowing in the presence of symptoms or objective signs of ischemia.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">610</enrollment>
  <condition>Arteriosclerosis of Arterial Coronary Artery Bypass Graft</condition>
  <arm_group>
    <arm_group_label>DES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug-eluting stents</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bare metal stents</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sirolimus-eluting stent</intervention_name>
    <description>due to randomization Cypher stent will be implanted</description>
    <arm_group_label>DES</arm_group_label>
    <other_name>Cypher</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>paclitaxel-eluting stent</intervention_name>
    <description>due to randomization Taxus stent will be implanted</description>
    <arm_group_label>DES</arm_group_label>
    <other_name>Taxus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>biodegradable-polymer-based sirolimus-eluting stent</intervention_name>
    <description>due to randomization a rapamycin-eluting stent with biodegradable polymer will be implanted</description>
    <arm_group_label>DES</arm_group_label>
    <other_name>ISAR-DES, Yukon PC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>bare metal stents</intervention_name>
    <description>Due to randomization one bare-metal stent will be implanted. The decision about the stent type will be up to the interventionalist</description>
    <arm_group_label>BMS</arm_group_label>
    <other_name>Multilink Vision</other_name>
    <other_name>Driver</other_name>
    <other_name>etc.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia
             in the presence of ≥ 50% de novo stenosis located in CABG

          -  Written, informed consent by the patient or her/his legally-authorized representative
             for participation in the study.

          -  In women with childbearing potential a negative pregnancy test is mandatory

        Exclusion Criteria:

          -  Cardiogenic shock

          -  Target lesion located in the native coronary vessels.

          -  In-stent restenosis of CABG

          -  Target lesion located at internal mammary artery graft or free arterial graft

          -  Malignancies or other comorbid conditions (for example severe liver, renal and
             pancreatic disease) with life expectancy less than 12 months or that may result in
             protocol non-compliance.

          -  Known allergy to the study medications: clopidogrel, rapamycin, paclitaxel, stainless
             steel.

          -  Inability to take clopidogrel for at least 6 months.

          -  Pregnancy (present, suspected or planned) or positive pregnancy test.

          -  Previous enrollment in this trial.

          -  Patient's inability to fully cooperate with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julinda Mehilli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzzentrum Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bad Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <last_update_submitted>May 12, 2011</last_update_submitted>
  <last_update_submitted_qc>May 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. A. Schömig</name_title>
    <organization>Deutsches Herzzentrum Munich</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

